CN Patent

CN116444426A — 微管蛋白-Src双靶点抑制剂和用途

Assigned to Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co · Expires 2023-07-18 · 3y expired

What this patent protects

本发明公开了一种微管蛋白‑Src双靶点抑制剂和用途。本发明提供了一种式I所示化合物、其立体异构体或其药学上可接受的盐；该化合物具有较好的微管蛋白聚合抑制作用。

USPTO Abstract

本发明公开了一种微管蛋白‑Src双靶点抑制剂和用途。本发明提供了一种式I所示化合物、其立体异构体或其药学上可接受的盐；该化合物具有较好的微管蛋白聚合抑制作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN116444426A
Jurisdiction
CN
Classification
—
Expires
2023-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.